Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.

Voon V, Schoerling A, Wenzel S, Ekanayake V, Reiff J, Trenkwalder C, Sixel-Döring F.

BMC Neurol. 2011 Sep 28;11:117. doi: 10.1186/1471-2377-11-117.

2.

[Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].

Bayard S, Cochen De Cock V, Dauvillers Y.

Geriatr Psychol Neuropsychiatr Vieil. 2011 Jun;9(2):227-35. doi: 10.1684/pnv.2011.0275. Review. French.

PMID:
21690031
3.

Compulsive habits in restless legs syndrome patients under dopaminergic treatment.

Pourcher E, Rémillard S, Cohen H.

J Neurol Sci. 2010 Mar 15;290(1-2):52-6. doi: 10.1016/j.jns.2009.11.010. Epub 2009 Dec 6.

PMID:
19969309
4.

Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.

Bayard S, Langenier MC, Dauvilliers Y.

Sleep. 2013 Oct 1;36(10):1501-7. doi: 10.5665/sleep.3044.

5.

Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O.

Clin Neuropharmacol. 2012 Nov-Dec;35(6):261-5. doi: 10.1097/WNF.0b013e31826e6e6d.

PMID:
23123689
6.

Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists.

Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH.

Neurology. 2007 Jan 23;68(4):301-3.

PMID:
17242339
7.

Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas.

Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P.

Clin Neuropharmacol. 2011 Sep-Oct;34(5):179-81. doi: 10.1097/WNF.0b013e3182281b2f.

PMID:
21738024
8.

The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

Dang D, Cunnington D, Swieca J.

Clin Neuropharmacol. 2011 Mar-Apr;34(2):66-70. doi: 10.1097/WNF.0b013e31820d6699.

PMID:
21412200
9.

Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome.

Möller JC, Körner Y, Cassel W, Meindorfner C, Krüger HP, Oertel WH, Stiasny-Kolster K.

Sleep Med. 2006 Jun;7(4):333-9. Epub 2006 Mar 22.

PMID:
16554184
10.

Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis.

Evans AH, Butzkueven H.

Mov Disord. 2007 Mar 15;22(4):590-1. No abstract available.

PMID:
17230484
11.

An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.

Stoner SC, Dahmen MM, Makos M, Lea JW, Carver LJ, Rasu RS.

Ann Pharmacother. 2009 Sep;43(9):1426-32. doi: 10.1345/aph.1M183. Epub 2009 Aug 18.

PMID:
19690226
12.

Parkinson's disease-related disorders in the impulsive-compulsive spectrum.

Wolters ECh, van der Werf YD, van den Heuvel OA.

J Neurol. 2008 Sep;255 Suppl 5:48-56. doi: 10.1007/s00415-008-5010-5. Review.

PMID:
18787882
13.

Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.

Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH.

Clin Neuropharmacol. 2007 Sep-Oct;30(5):249-55.

PMID:
17909302
14.

Impact of dopamine agonists on compulsive behaviors: a case series of pramipexole-induced pathological gambling.

Kolla BP, Mansukhani MP, Barraza R, Bostwick JM.

Psychosomatics. 2010 May-Jun;51(3):271-3. doi: 10.1176/appi.psy.51.3.271.

PMID:
20484726
15.

Dopamine dysregulation syndrome in a patient with restless legs syndrome.

Leu-Semenescu S, Karroum E, Brion A, Konofal E, Arnulf I.

Sleep Med. 2009 Apr;10(4):494-6. doi: 10.1016/j.sleep.2008.12.010.

PMID:
19410183
16.

Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome.

Schreglmann SR, Gantenbein AR, Eisele G, Baumann CR.

Parkinsonism Relat Disord. 2012 Feb;18(2):207-9. doi: 10.1016/j.parkreldis.2011.10.010. Epub 2011 Oct 26.

PMID:
22030321
17.

Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.

Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH.

Sleep. 2010 Jan;33(1):81-7.

18.

Treatment wish of individuals with known and unknown restless legs syndrome in the community.

Happe S, Vennemann M, Evers S, Berger K.

J Neurol. 2008 Sep;255(9):1365-71. doi: 10.1007/s00415-008-0922-7. Epub 2008 Jun 27.

PMID:
18575924
19.

Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.

Joutsa J, Martikainen K, Vahlberg T, Kaasinen V.

Parkinsonism Relat Disord. 2012 Dec;18(10):1079-83. doi: 10.1016/j.parkreldis.2012.06.005. Epub 2012 Jul 10.

PMID:
22784693
20.

A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.

Poletti M, Logi C, Lucetti C, Del Dotto P, Baldacci F, Vergallo A, Ulivi M, Del Sarto S, Rossi G, Ceravolo R, Bonuccelli U.

J Clin Psychopharmacol. 2013 Oct;33(5):691-4. doi: 10.1097/JCP.0b013e3182979830.

PMID:
23857310

Supplemental Content

Support Center